Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity. 2020

Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

: Human α-calcitonin gene-related peptide (h-α-CGRP) is a highly potent vasodilator peptide that belongs to the family of calcitonin peptides. There are two forms of CGRP receptors in humans and rodents: α-CGRP receptor predominately found in the cardiovascular system and β-CGRP receptor predominating in the gastrointestinal tract. The CGRP receptors are primarily localized to C and Aδ sensory fibers, where they are involved in nociceptive transmission and migraine pathophysiology. These fibers are found both peripherally and centrally, with extensive perivascular location. The CGRP receptors belong to the class B G-protein-coupled receptors, and they are primarily associated to signaling via Gα proteins. The objectives of the present work were: (i) synthesis of three single-labelled fluorescent analogues of h-α-CGRP by 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase peptide synthesis, and (ii) testing of their biological activity in isolated human, mouse, and rat arteries by using a small-vessel myograph setup. The three analogues were labelled with 5(6)-carboxyfluorescein via the spacer 6-aminohexanoic acid at the chain of Lys24 or Lys35. Circular dichroism (CD) experiments were performed to obtain information on the secondary structure of these fluorescently labelled peptides. The CD spectra indicated that the folding of all three analogues was similar to that of native α-CGRP. The three fluorescent analogues of α-CGRP were successfully prepared with a purity of >95%. In comparison to α-CGRP, the three analogues exhibited similar efficacy, but different potency in producing a vasodilator effect. The analogue labelled at the N-terminus proved to be the most readily synthesized, but it was found to possess the lowest vasodilator potency. The analogues labelled at Lys35 or Lys24 exhibited an acceptable reduction in potency (i.e., 3-5 times and 5-10 times less potent, respectively), and thus they have potential for use in further investigations of receptor internalization and neuronal reuptake.

UI MeSH Term Description Entries
D008297 Male Males
D008881 Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) Acute Confusional Migraine,Headache, Migraine,Status Migrainosus,Abdominal Migraine,Cervical Migraine Syndrome,Hemicrania Migraine,Migraine,Migraine Headache,Migraine Variant,Sick Headache,Abdominal Migraines,Acute Confusional Migraines,Cervical Migraine Syndromes,Disorder, Migraine,Disorders, Migraine,Headache, Sick,Headaches, Migraine,Headaches, Sick,Hemicrania Migraines,Migraine Disorder,Migraine Headaches,Migraine Syndrome, Cervical,Migraine Syndromes, Cervical,Migraine Variants,Migraine, Abdominal,Migraine, Acute Confusional,Migraine, Hemicrania,Migraines,Migraines, Abdominal,Migraines, Acute Confusional,Migraines, Hemicrania,Sick Headaches,Variant, Migraine,Variants, Migraine
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D005452 Fluoresceins A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays. Tetraiodofluorescein
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000200 Action Potentials Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli. Spike Potentials,Nerve Impulses,Action Potential,Impulse, Nerve,Impulses, Nerve,Nerve Impulse,Potential, Action,Potential, Spike,Potentials, Action,Potentials, Spike,Spike Potential
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D015119 Aminocaproic Acid An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. 6-Aminocaproic Acid,6-Aminohexanoic Acid,epsilon-Aminocaproic Acid,Amicar,CY-116,Capralense,Capramol,Caproamin,Caprocid,Caprolest,Epsamon,Epsikapron,Hemocaprol,Hexalense,6 Aminocaproic Acid,6 Aminohexanoic Acid,CY 116,CY116,epsilon Aminocaproic Acid

Related Publications

Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
October 1986, The Journal of investigative dermatology,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
January 1985, Nature,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
July 1985, Lancet (London, England),
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
April 1986, Clinical science (London, England : 1979),
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
May 1986, European journal of pharmacology,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
December 1988, British journal of clinical pharmacology,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
March 1992, Biochemical pharmacology,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
September 1988, Nature,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
December 2013, British journal of pharmacology,
Jing Zhu, and Mahdieh Dagina Pedersen, and Laraib Sabbah Ahmed, and Bahareh Abdolalizadeh, and Anne-Sofie Grell, and Jais Oliver Berg, and Peter Waaben Thulstrup, and Henrik Franzyk, and Lars Edvinsson, and Anette Sams, and Majid Sheykhzade, and Paul Robert Hansen
September 1991, Experimental eye research,
Copied contents to your clipboard!